Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group

Abstract

The two regimens are equally active. Myelotoxicity is worse in the CG group whereas alopecia, myalgia and neurotoxicity worse in the PG group.

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

“…Reasons for exclusion were not stated in eight studies [30,31,40,42,43,48,57,64], whereas we were unable to assess if any exclusion criteria were applied in a trial published in Chinese only [46]. Response was assessed according to the World Health Organization standard criteria [72] in 19 trials [22,23,25,29,32,34,35,39,44,45,47,49,50,52,53,59,62,65,68], according to the Southwest Oncology Group guidelines [73] in two studies [21,24], and according to the Response Evaluation Criteria in Solid Tumors [74] in four trials [60,61,66,67].…”

Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

“…Grade 3 and 4 hemathologic toxicities were seen; neutropenia 6-22%, trombocytopenia 1-7%, anemia 1.6-6%. Grade 3/4 non-hemathologic toxicities were seen; neurotoxicity 3.5-6.8%, nephrotoxicity 0-0.5%,, hepatotoxiciy 0-7%, pulmoner toxicity 0-13.8 (Isla et al, 2001;Smit et al, 2003;Kosmidis et al, 2008;Pino et al, 2008;Comellaa et al, 2010).…”

“…Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality and the incidence is increasing among women (Kosmidis et al, 2008). The American Cancer Society has estimated that the number of new lung cancer cases in the United States will be 114,690 in men and 100,330 in women for 2008.…”

“…The American Cancer Society has estimated that the number of new lung cancer cases in the United States will be 114,690 in men and 100,330 in women for 2008. Among them, 161,840 are expected to die from this disease (Shepherd et al, 1993;Huang et al, 2008;Kosmidis et al, 2008;De et al, 2011). Most patients (>80%) have locally advanced stage III or metastatic stage IV NSCLC at the time of diagnosis and are ineligible for potentially curative surgery, and 5-year survival is <10% in this patient population (Shepherd et al, 1993;Walling et al, 1994;Caponi et al, 2010;De et al, 2011).…”

“…Non-platinum combinations can also provide modest survival benefits and improvements in quality of life, but these combinations have yet to be broadly accepted (Georgoulias et al, 2005;Treat et al, 2005;Takeda et al, 2009). During the past few years, several novel drugs including paclitaxel, docetaxel, pemetrexed, gemcitabine, vinorelbine, erlotinib, gefitinib have shown significant activity against NSCLC (Shepherd et al, 1993;Walling et al, 1994;Fosella et al, 2000;Smit et al, 2003;Delbaldo et al, 2004;Huang et al, 2008;Kosmidis et al, 2008;Di et al, 2010;Klastersky et al, 2012). As a single agent in advanced NSCLC, gemcitabine has produced response rates of between 20% and 28% and survivals between 7 and 11 months (Anderson et al, 1994;.…”